{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Thymosin Beta-4",
    "short_name": "Thymosin Beta-4",
    "aliases": [
      "tb4",
      "tβ4"
    ],
    "classification": {
      "category": "investigational_human",
      "needs_prescription": false,
      "notes": "Classification describes what Thymosin Beta-4 is and the general domain where it appears."
    },
    "status": {
      "category": "investigational_human",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-19",
      "human_use_note": "Status reflects how Thymosin Beta-4 appears in clinical literature, regulatory contexts, and real-world use. This is descriptive only."
    },
    "structure": {
      "sequence_oneletter": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "amino_acid_seq": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_formula": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_weight": null,
      "structure_image_url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "risk": {
      "current_score": 5,
      "severity": "moderate",
      "likelihood": "possible",
      "evidence_grade": "unknown",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Risk reflects evidence quality, adverse-signal plausibility, and uncertainty. Limited data increases uncertainty.",
      "risk_score": 5
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Thymosin Beta-4 is a bioactive compound discussed in research and/or clinical contexts. This entry summarizes what it is, what it is studied for, and what evidence does and does not support, without providing protocols.",
          "evidence_refs": [
            "E1"
          ]
        }
      ],
      "use_cases": [],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "unit": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "min": null,
          "max": null,
          "frequency": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "duration": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "population_group": "general",
          "notes": "Descriptive only. Observed in studies; not instructions.",
          "evidence_refs": []
        }
      ],
      "developmental_risk_block": [
        {
          "claim_type": "risk",
          "population_group": "adolescent",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.",
          "evidence_refs": []
        }
      ],
      "interaction_summary": [],
      "current_outlook_bullets": [
        "a bioactive compound discussed in research and/or clinical contexts",
        "this entry summarizes what it is, what it is studied for, and what evidence does and does not support, without providing protocols",
        "tendon and ligament recovery support",
        "soft tissue healing after overuse or injury",
        "return-to-training support during rehab",
        "joint comfort and mobility support",
        "interest in tissue repair pathways"
      ]
    },
    "evidence": [
      {
        "id": "E1",
        "title": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "source_type": "pubmed",
        "source_id": "E1",
        "url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "published_date": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "evidence_grade": "unknown",
        "notes": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
      }
    ],
    "changelog": [
      {
        "date": "2026-01-19",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for Thymosin Beta-4",
        "detail": "Generated from queue ingestion (Phase 6). Requires human-authored, evidence-bounded content.",
        "evidence_refs": []
      }
    ],
    "meta": {},
    "topics": {
      "primary": [
        "topic_injury_healing",
        "topic_muscle_recovery"
      ]
    },
    "slug": "thymosin-beta-4",
    "practical": {
      "schema_version": "practical_block_v1",
      "bottom_line": "Thymosin beta-4 is discussed for tissue repair and recovery, with most supportive data coming from preclinical models and limited human research. In real-world use discussions, it is often framed around injury recovery and return-to-training timelines. Product labeling and market naming can be confusing, so identity and sourcing are major practical risks.",
      "benefits": [
        "Soft-tissue recovery interest after overuse or injury",
        "Skin and wound recovery interest in research contexts",
        "Joint comfort and mobility support interest during rehab periods",
        "Interest in repair-pathway signaling in sports medicine discussions"
      ],
      "side_effects_common": [
        "Injection-site irritation or discomfort",
        "Headache",
        "Nausea",
        "Fatigue"
      ],
      "side_effects_serious": [
        "Allergic reaction with hives, facial swelling, or trouble breathing",
        "Chest pain, fainting, or severe shortness of breath",
        "Severe swelling, rapidly spreading redness, or drainage at an injection site"
      ],
      "who_should_be_cautious": [
        "Active cancer or recent cancer treatment",
        "People using anticoagulants or antiplatelets",
        "Bleeding disorders",
        "Pregnancy or breastfeeding",
        "Children and adolescents"
      ]
    }
  },
  "canonical_name": "Thymosin Beta-4",
  "interactions": {
    "drug_classes": [
      "anticoagulants-antiplatelets"
    ],
    "supplement_classes": [
      "anticoagulant-herbs"
    ],
    "peptides": []
  },
  "practical": {
    "schema_version": "practical_block_v1",
    "bottom_line": "Thymosin beta-4 is discussed for tissue repair and recovery, with most supportive data coming from preclinical models and limited human research. In real-world use discussions, it is often framed around injury recovery and return-to-training timelines. Product labeling and market naming can be confusing, so identity and sourcing are major practical risks.",
    "benefits": [
      "Soft-tissue recovery interest after overuse or injury",
      "Skin and wound recovery interest in research contexts",
      "Joint comfort and mobility support interest during rehab periods",
      "Interest in repair-pathway signaling in sports medicine discussions"
    ],
    "side_effects_common": [
      "Injection-site irritation or discomfort",
      "Headache",
      "Nausea",
      "Fatigue"
    ],
    "side_effects_serious": [
      "Allergic reaction with hives, facial swelling, or trouble breathing",
      "Chest pain, fainting, or severe shortness of breath",
      "Severe swelling, rapidly spreading redness, or drainage at an injection site"
    ],
    "who_should_be_cautious": [
      "Active cancer or recent cancer treatment",
      "People using anticoagulants or antiplatelets",
      "Bleeding disorders",
      "Pregnancy or breastfeeding",
      "Children and adolescents"
    ]
  }
}
